Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa

• Status: Not yet recruiting
• Trial end date: 2027-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

Title: Implementing oral (event-driven and daily) and long-acting Pre-exposure prophylaxis (PrEP) in mobile men in Sub-Saharan Africa

Design: A mixed method, multi-setting, multi-country, phase 3b, open-label, hybrid type 2 implementation and effectiveness randomized controlled trial (RCT). The trial will be carried out in 400 HIV negative men aged 18+ years in South Africa and Uganda. Men will be randomized 1:1 to either Group A: oral Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC) PrEP (event-driven or daily) or Group B: Long-acting injectable cabotegravir (CAB-LA) over 9-months. After 9-months participants from both groups will be offered choice of PrEP (oral TDF-FTC or CAB-LA) for a further 9-months, with the ability to change choice as required. Various strategies to support PrEP adoption, initiation, and persistence will be implemented, monitored, and reported on using a RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) implementation science framework.

Treatment: CAB-LA or oral TDF-FTC Duration: 18 months

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: MRC/UVRI and LSHTM Uganda Research Unit
• Collaborators: Africa Health Research Institute; Assistance Publique - Hôpitaux de Paris; Desmond Tutu HIV Foundation; King's College London; London School of Hygiene and Tropical Medicine; Ministry of Health, Uganda; University College, London; Wits Health Consortium (Pty) Ltd
• Treatments: Cabotegravir; Emtricitabine; Tenofovir

Criteria

Inclusion Criteria:

1. Able and willing to provide informed consent

2. Aged 18 years and above on the day of screening

3. Willing to have a HIV test and receive the test results

4. Male at birth

5. In the past 6-months has travelled for work or to find work and spent at least one night away from home for work related purposes.

6. Available for follow up for the duration of the study

Exclusion Criteria:

1. Known HIV infection

2. Confirmed HIV-positive test result, indeterminate HIV test result, and/or signs and symptoms of an acute HIV infection

3. Body weight less than 35Kg at baseline

4. Allergy to any of the study products

5. Medical, social or other condition that, in the opinion of the site investigator, would interfere with the conduct of the study or safety of the participant (e.g., provided by self-report, or found upon medical history and examination or in available medical records)

6. Use of contraindicated medications: Medication for tuberculosis (Rifampin, rifapentine) or anticonvulsants (Carbamazepine, oxcarbazepine, phenobarbital, phenytoin)

7. Other reasons at the discretion of site investigator for unsuitability for study inclusion